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SHORT COMMUNICATION
Human papillomavirus type 18 is associated with less apoptosis in
fibroblast tumours than human papillomavirus type 16
MJ Arends, AH Wyllie and CC Bird
CRC Laboratories, Department ofPathology,. UniversityMedical School, Teviot Place, Edinburgh EH8 9AG, -K.
Sumanr In human cervical neoplasia human papillomaVirus (HPV) type 18 has a higher cancer cervical
intraepithelial neoplasia (CIN) prevalence ratio than HPV 16. Fibrosarcomas derived from rat fibroblasts
transfected with HPV 16 or 18 genomes showed increased apoptosis compared with controls. However. HPV
18 was associated with significantlx less apoptosis than HPV 16. affording one possible explanation for the
more rapidly progressive cervical neoplasia associated with HPV 18.
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There is strong evidence for a contribution by human papill-
omaviruses (HPVs) to the development of cervical intra-
epithelial neoplasia (CIN) lesions and cerVical cancer. but the
precise mechanisms are still controversial (Arends et al..
1990: zur Hausen. 1994). Clinical and experimental data
point to an association of the two common high-risk genital
types. HPV 16 and 18. with formation of high-grade
premalignant lesions (CIN 2 and 3) (Gissmann. 1984: de Vill-
iers et al.. 1987: Arends et al.. 1991. 1993a: Lorincz et al..
1992: Schiffman et al.. 1993). The largest increase in
prevalence of HPV 16 and 18 in the spectrum of cervical
neoplasia occurs between CIN I and CIN 2 3 (Arends et
al.. 1991. 1993a; Lorincz et al.. 1992). and these types max%
be found in up to 90° 0 of cervical cancers (Xiao et al..
1988: StanleN-. 1990: Schiffman et al.. 1993). In contrast. the
low-risk types. HPV 6b. 11 and others. are most frequentlx
found in genital warts and CIN 1 (Pater et al.. 1986: de
Villiers et al.. 1987: Schiffman et al.. 1991). Different HPV
types. associated with CIN 2 3 lesions. may differentiallv
influence the risk of progression of CIN 2 3 to invasive
cervical cancer. An approximate measure of the risk of
transition from precursor lesion to cancer associated with a
particular HPV tvpe can be calculated using the ratio of
HPV-tNpe prevalence in squamous cancers to that in d s-
plastic squamous intraepithelial lesions (cancer CIN prev-
alence ratio). Several studies have shown that HPV 18 is
associated with a higher cancer CIN ratio than HPV 16
(Kurman et al.. 1988: Lorincz et al.. 1992: Arends et al..
1993a). suggesting that HPV 18 is associated more often
than HPV 16 with dysplastic lesions having the capacity for
evolution to cancer. but this observation remains largely
unexplained at the cellular level.
At the cellular level the net tumour growth rate reflects
the balance of cell gain and loss (Wyllie. 1985: Arends et
al.. 1994). and in CIN lesions. cell gain is by proliferation
and cell loss by apoptosis and surface shedding. HPVs do
not appear to influence proliferation rates in CIN lesions.
since there are no differences in Ki-67 expression between
HPV-positive and -negative CIN biopsies (Tervahauta et
al.. 1994). Apoptosis may therefore represent a key
mechanism bx- which different HPV types influence net
growth rates of CIN. The threshold for susceptibilitv to
apoptosis or its intnnsic rate within tumours. is regulated
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by many oncogenes and tumour-suppressor genes. such as
up-regulation by c-mvc or wild-type p53. or down-regul-
ation by mutated ras. bcl-2 or Rb (Arends and Wyllie. 1991:
Clarke et al.. 1992. 1993: Evan et al.. 1992: Shaw et al..
1992: Arends et al.. 1993b; Arends and Harrison. 1994:
Morgenbesser et al.. 1994). The intracellular availability of
the products of some of these genes is known to be directly
affected by the E6 and E7 oncoproteins of HPV 16 and 18.
but there is no information on the levels of apoptosis
associated with HPV 16 as compared with HPV 18. or on
the relationship of this to tumour growth. in CIN or indeed
in any cell type. Here. we address these questions by com-
paring the behaviour of fibroblast lines growing as tumours
in vivo. derived from a common immortalised parent by
transfection with HPV 16 or 18 genomes.
Materials and methods
The parent cell line was the Fischer rat lung fibroblast 208F
(Quade. 1979). and transfectants were derived from it as
previously described (Arends et al.. 1993b. 1994). bearing
(1) HPV genomes of types 16 or 18 (Storey et al.. 1988).
without (H16 and H18) or with (H16R and H18R) the
plasmid pHO5Tl (Spandidos and Wilkie. 1984) that exp-
ressed the human T24-Ha-ras-1 oncogene with a point
mutation at codon 12: (2) only the T24-ras expression vec-
tor pHOSTl (Ti) (Spandidos and Wilkie. 1984): and (3)
only the c-mvc expression plasmid pHRMCGMI (M8)
(Arends et al.. 1993b). Approximately 10 million cells were
injected subcutaneously into the groins of between 6 and 11
immunosuppressed CBA mice. prepared as previously des-
cribed (Wyllie et al.. 1987: Arends et al.. 1994). for each cell
line. Animals were subjected to autopsy after 12 days. All
analytical techniques were as described prev-iously- (Arends
et al.. 1993b. 1994). In brief. the size of tumours growing at
the injection site was measured in three dimensions in mill-
imetres. and these were multiplied together to give a
nominal 'box volume' convenient for comparisons. Repres-
entative equatorial blocks of tumour were fixed in formalin.
processed and stained with haematoxylin and eosin. The
number of mitotic and apoptotic figures were counted per
ten high-power fields. for at least six tumours formed by
each cell line. Tumour necrosis was assessed on a four-point
scale. The raw data for mitotic counts and apoptotic counts
were combined to form ratios of apoptosis mitosis (A M) in
an attempt to correct for bias introduced into these counts
through differences in cell size and packinz density.ads HPV 16/18
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Results
Fibroblast tumours formed by all transfected cell lines.
except H18R, had significantly higher absolute levels of
apoptosis than the small nodules generated by the parent
cell line 208F (P<0.00001 for all comparisons, except for
TI vs 208F, P<0.05) (Figure 1). HPV 18 consistently dem-
onstrated lower absolute levels of apoptosis than HPV 16,
either alone (P<0.00001 for H16 vs H18) or in combination
with T24-ras (P<0.00001 for H16R vs H18R). Tumours of
transfectants containing either HPV 16 or 18 showed apop-
totic counts similar to those of the c-mYc transfectant M8.
but H16 showed significantly higher levels of apoptosis
(P<0.00001), whereas H18 formed tumours with lower
apoptotic counts that did not significantly differ from M8.
T24-ras in combination with either HPV-type generated
tumours with significantly less apoptosis than transfectants
containing HPV alone (P<0.00001 for both H16R vs H16,
and H18R vs H18). The values for tumour cell proliferat-
ion, as determined by the mitotic counts, were similar for
the four HPV-containing transfectants (Figure 1). The only
significant differences in mitotic counts were between H16
and either H18 or H18R (P<0.0005 for both comparisons)
and these were relatively small compared to the differences
in apoptotic counts.
All transfectants generated tumours which were larger in
size than the static or regressing nodules formed by the
parent cell line 208F (Figure 1). Tumours formed by H18
were larger than those formed by H16. However, H16R
tumours were similar in size to those formed by H18R, both
of which showed marked central necrosis. Student's t-tests
showed significant differences in tumour size between 208F
and the transfectants H16R (P<0.0001), H18 (P=0.035),
and TI (P<0.0001); and also between H16 and H16R
(P= 0.0037).
Companrsons ofcell turnover parameters with tumour sizes
for the four HPV-containing transfectants (H16, H18, H16R
and H18R) showed that apoptotic counts inversely correlated
with tumour sizes (r =-0.79), whereas mitotic counts
positively correlated with tumour sizes (r = 0.85). The A/M
ratios also correlated inversely with tumour sizes (r = -0.87).
Overall, for all seven cell lines, including 208F, M8 and TI,
log A/M ratios showed an inverse correlation with tumour
sizes (r =-0.81; regression equation log A/M = 1.16-
1.55 x size; P = 0.029) and with log tumour sizes (r=-0.93;
regression equation log A/M =-0.805-1.31 x log size;
P = 0.002).
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The two common high-nrsk genital HPV types were assoc-
iated with moderate to high levels of tumour cell apoptosis.
similar in degree to that stimulated by c-myc, previously
shown to be a potent inducer of apoptosis (Wyllie et al..
1987; Evan et al., 1992; Arends et al.. 1993b. 1994). HPV 18
was associated with lower levels of tumour apoptosis than
HPV 16. and this pattern was not modulated by the presence
of T24-ras. The sizes of tumours correlated inversely with
both the absolute levels of apoptosis and the ratios of
apoptosis,mitosis. Thus, the intrinsic rate of apoptosis within
tumours is differentially modulated by HPV type and appears
to be a major regulator of net growth rate.
Possible mechanisms by which HPV 16 and 18 E7 proteins
may stimulate apoptosis include the binding and inactivation
of Rb protein (Phelps et al.. 1988; Munger et al., 1989, 1991).
resulting in several consequences: first, prevention of an Rb
anti-apoptotic effect (Clarke et al.. 1992; Morganbesser et al..
1994); second, release of both c-myc and E2F-1 proteins from
complexes with Rb (Rustgi et al.. 1991; Wagner and Green.
1991); and third, release of repression of c-mwc transcription
(Moses et al., 1990; Pietenpol et al., 1990; Chittenden et al..
1991). Both c-myc and E2F-1 are associated with induction
of apoptosis (Evan et al.. 1992; Moran. 1993; Wu and
Levine, 1994) as well as proliferation and this pathway may
explain the similan'ties of levels of tumour cell apoptosis
shown here between HPV 16/18 and mvc transfectants. HPV
E7 transgenic mice have been used to confirm the induction
of apoptosis by cell specific expression of E7 (Howes et al..
1994; Pan and Griep, 1994).
HPV 16 and 18 E6 products have apoptosis-suppressing
effects, as they both bind p53 and direct its rapid degradation
(Werness et al., 1990; Scheffner et al.. 1991). Wild-type p53
(but not mutant p53) has been shown to induce apoptosis in
myeloid, lymphoid and epithelial cells (Yonish-Rouach et al.,
1991; Shaw et al., 1992; Clarke et al., 1993, 1994), and
studies in both fibroblast cell lines and transgenic mice have
suggested that E6 can block the apoptosis-inducing function
of p53 in the presence of HPV E7 (Howes et al., 1994; Pan
and Griep, 1994; White et al.. 1994). Thus, the two HPV
transforming genes have opposing effects on apoptosis:
stimulation via HPV E7-mediated inactivation of Rb with
activation of both mvc and E2F-I and inhibition via HPV
E6-mediated degradation of wild-type p53. The relative
strengths of these activities will be affected by the com-
parative levels of expression of E7 and E6, and their relative
Cell line
Figure 1 Bar chart of growth properties of tumours derived from the parent control (208F), a c-mwc transfectant (M8), four
HPV-containing transfectants (H16, H16R, H18, H18R) and a T24-ras transfectant (TI). The means ( ± s.e.m. as error bars) of
mitotic and apoptotic counts per ten high-power fields for six tumours are shown, along with tumour sizes in cm3. . Mitosis;
. apoptosis; M. size.ApopMsisAnd HPV 16/1
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efficiencies in terms of protein function and stability. One
speculative explanation for the lower levels of apoptosis
associated with HPV 18 is that there may be saturation of
the pro-apoptotic E7-Rb-E2F-myc pathway by both HPV
types (both show increases in apoptosis above control levels
that are similar to mic-induced levels), but higher activity of
the anti-apoptotic E6-p53 pathway associated with HPV 18
owing to greater concentrations of HPV 18 E6 (compared
with HPV 16 E6), because of the more efficient upstream
regulatory region of HPV 18 producing higher levels of
expression of the E6 gene (Barbosa and Schlegel. 1989:
Romanczuk et al.. 1991).
Phenotypic analysis of authentic human cervical cancers
containing HPV 16 and 18 genomes has indicated that HPV
18 is associated with greater aggression than HPV 16 in
terms of progression from CIN to cancer, assessed by cancer
CIN prevalence ratios (Kurman et al., 1988; Lorincz et al..
1992: Arends et al.. 1993a). If the lower apoptosis and faster
growth rate associated with HPV 18 compared with HPV 16
in this fibroblast system also occurred in cervical kerat-
inocytes in CIN lesions in vivo. this would result in more
rapid production of CIN cells, increasing the probability of
further genetic changes required for transition to malignancy,
such as integration of the HPV genome, activation of cellular
oncogenes or loss of oncosuppressor genes. Furthermore.
selection pressures may be different, in that reduced apop-
tosis due to greater inactivation of p53 by HPV 18 E6 may
allow survival of DNA-damaged cells that would otherwise
die by p53-induced apoptosis after genotoxic injury.
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